A Systematic Assessment of Absolute Treatment Effect

American Journal of Cardiology

Volumn 116, Issue 5, 2015, Pages 829-831

  Ferreira, João Pedro ^a   Coiro, Stefano ^a   Girerd, Nicolas ^a  

^a NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPLERENONE;

CARDIAC RESYNCHRONIZATION THERAPY; DISEASE SEVERITY; HEART FAILURE; HEART LEFT BUNDLE BRANCH BLOCK; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; NOTE; PRIORITY JOURNAL; SURVIVAL RATE; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME; FEMALE; MALE; PROCEDURES; TRENDS;

CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE;

EID: 84944685324     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.07.023     Document Type: Letter

References (9)

1. A.Y. Lee, A.J. Moss, M.H. Ruwald, V. Kutyifa, S. McNitt, B. Polonsky, W. Zareba, and A.C. Ruwald Temporal influence of heart failure hospitalizations prior to implantable cardioverter defibrillator or cardiac resynchronization therapy with defibrillator on subsequent outcome in mild heart failure patients (from MADIT-CRT) Am J Cardiol 115 2015 1423 1427
2. N. Girerd, M. Rabilloud, K. Duarte, and P. Roy Number needed to treat from absolute risk and incidence rate: how to make apples and oranges comparable? J Clin Epidemiol 67 2014 236 238
3. N. Girerd, P. Rossignol, and F. Zannad Fibrinolysis for intermediate-risk pulmonary embolism N Engl J Med 371 2014 579
4. N. Girerd, T. Collier, S. Pocock, H. Krum, J.J. McMurray, K. Swedberg, D.J. Van Veldhuisen, J. Vincent, B. Pitt, and F. Zannad Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial Eur Heart J 2015 (in press), pii: ehv273
5. T.J. Collier, S.J. Pocock, J.J. McMurray, F. Zannad, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, and B. Pitt The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial Eur Heart J 34 2013 2823 2829
6. G.A. Diamond, and S. Kaul On reporting of effect size in randomized clinical trials Am J Cardiol 111 2013 613 617
7. K. Singh, K. Carson, R. Shah, G. Sawhney, B. Singh, A. Parsaik, H. Gilutz, Z. Usmani, and J. Horowitz Meta-analysis of clinical correlates of acute mortality in takotsubo cardiomyopathy Am J Cardiol 113 2014 1420 1428
8. M.K. Campbell, G. Piaggio, D.R. Elbourne, and D.G. Altman Consort 2010 statement: extension to cluster randomised trials BMJ 345 2012 e5661
9. R.G. White, A.J. Hakim, M.J. Salganik, M.W. Spiller, L.G. Johnston, L. Kerr, C. Kendall, A. Drake, D. Wilson, K. Orroth, M. Egger, and W. Hladik Strengthening the Reporting of Observational Studies in Epidemiology for Respondent-Driven Sampling Studies: "STROBE-RDS" statement J Clin Epidemiol 2015 (in press), pii: S0895-4356(15)00171-7 http://dx.doi.org/10.1016/j.jclinepi.2015.04.002